CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC Mechanism of Action — Growth Hormone Pulse

Q: How does CJC-1295 no DAC differ from peptides that directly release growth hormone?

CJC-1295 no DAC is a GHRH analogue that signals the pituitary to release endogenous growth hormone through the natural receptor pathway, whereas direct GH secretagogues (like GHRP-2 or GHRP-6) bypass GHRH receptors entirely and bind to ghrelin receptors. The GHRH pathway preserves physiological pulse structure and is subject to somatostatin gating, while ghrelin receptor agonists can override somatostatin inhibition but may disrupt natural pulse timing. Neither approach is superior — they serve different protocol goals depending on whether pulse fidelity or magnitude is prioritised.

Q: Can CJC-1295 no DAC be used continuously without receptor desensitisation?

Yes, when dosed correctly. The peptide’s 30-minute half-life allows it to clear between endogenous GH pulses, which gives GHRH receptors time to recycle and resensitise. Protocols using 1–3 daily injections timed around natural pulse windows maintain receptor responsiveness across 12–16 week cycles in research settings. Continuous use of DAC-conjugated variants, by contrast, typically shows receptor downregulation and diminished GH response within 8–12 weeks due to sustained receptor occupancy.

Q: What is the optimal injection timing relative to meals and sleep?

Administer CJC-1295 no DAC at least 2 hours after meals to avoid postprandial somatostatin inhibition, and ideally during windows of low somatostatin tone — upon waking (aligning with the morning GH pulse), 30–45 minutes pre-workout (when GH pulses naturally occur during physical stress), or immediately before sleep (to amplify the largest endogenous pulse of the day). Injecting within 90 minutes of a carbohydrate-rich meal significantly blunts GH response regardless of dose.

Q: Does CJC-1295 no DAC require co-administration with a GHRP for maximum effect?

Not required, but synergistic. GHRH analogues like CJC-1295 no DAC and ghrelin receptor agonists (GHRPs) act through separate pathways — GHRH increases GH pulse amplitude, while GHRPs increase pulse frequency and can override somatostatin. Co-administration produces a multiplicative effect on total GH output, but also increases the risk of supraphysiological IGF-1 elevation and insulin resistance. Single-agent protocols using CJC-1295 no DAC alone are sufficient for moderate GH amplification without disrupting pulse architecture.

Q: How long does reconstituted CJC-1295 no DAC remain stable?

Reconstituted with bacteriostatic water and stored at 2–8°C, the peptide maintains structural integrity for 28–30 days. Any temperature excursion above 8°C accelerates aggregation and denaturation — even brief exposure (4–6 hours at room temperature) can compromise potency. Lyophilised (unreconstituted) peptide is stable at room temperature for 12–18 months, but once mixed with water, refrigeration is non-negotiable. Freezing reconstituted peptide causes ice crystal formation that irreversibly damages the amino acid structure.

Q: What are the signs that CJC-1295 no DAC has lost potency?

There are no reliable visual indicators — denatured peptide looks identical to active peptide in solution. The only functional test is absence of expected physiological response (no increase in perceived recovery, sleep quality, or measurable IGF-1 elevation after 7–10 days of consistent dosing). This is why proper storage and reconstitution technique are critical — peptide degradation is silent until you observe lack of effect, at which point the vial’s contents are already compromised.

Q: Can CJC-1295 no DAC cause receptor downregulation if dosed too frequently?

Receptor downregulation occurs when occupancy duration exceeds the receptor recycling window, not when dosing frequency is high. Three daily injections of no DAC spaced 6–8 hours apart allow receptors to clear and resensitise between doses, preserving responsiveness. The critical variable is half-life: a peptide that clears in 30 minutes allows receptor recycling; a peptide with a 6-day half-life (like DAC variants) does not. Frequency itself is not the issue — sustained occupancy is.

Q: How does sleep quality affect CJC-1295 no DAC efficacy?

Sleep — specifically slow-wave sleep (stages 3 and 4) — is when the largest endogenous GH pulse of the day occurs. CJC-1295 no DAC administered before sleep amplifies this pulse, but if sleep architecture is disrupted (due to sleep apnea, insufficient duration, or frequent waking), the baseline pulse it’s meant to amplify is already blunted. The peptide cannot compensate for absent or fragmented sleep-related GH secretion — it amplifies what’s there, not creates what isn’t. Chronic sleep deprivation reduces protocol efficacy regardless of dosing strategy.

Q: What is the expected IGF-1 increase from CJC-1295 no DAC monotherapy?

IGF-1 elevation from CJC-1295 no DAC alone is modest — typically 15–30% above baseline after 4–6 weeks of consistent dosing at 100–200mcg per injection, 1–3 times daily. This reflects amplified GH pulses driving hepatic IGF-1 synthesis without the continuous GH exposure that produces supraphysiological IGF-1 (>400 ng/mL). Individuals starting with low baseline IGF-1 (<150 ng/mL) often see proportionally larger increases. Co-administration with GHRPs can double or triple IGF-1 response due to synergistic GH output.

Q: Does CJC-1295 no DAC affect natural growth hormone production after discontinuation?

No suppression of endogenous GH occurs with CJC-1295 no DAC because the peptide works through the natural GHRH receptor pathway — it does not replace or suppress hypothalamic GHRH release. Upon discontinuation, GH pulse amplitude and frequency return to baseline within 48–72 hours as the peptide clears and exogenous receptor stimulation ceases. This is distinct from exogenous GH administration, which suppresses endogenous secretion and requires a taper period to restore natural pulsatility.

Real Peptides Research TeamEditorial

Updated April 9, 202611 min read

49 WORDS

Short answer

Dynamics Research published in the Journal of Clinical Endocrinology & Metabolism found that synthetic GHRH analogues with shortened half-lives preserve physiological growth hormone (GH) pulse amplitude while avoiding the receptor desensitisation seen with continuous GHRH exposure. CJC-1295 no DAC (also called Modified GRF 1-29) operates through this exact mechanism.

Key takeaways

CJC-1295 no DAC binds to GHRH receptors on pituitary somatotrophs, activating the cAMP-PKA-calcium signalling cascade to trigger growth hormone exocytosis within 15–30 minutes of subcutaneous administration.
The peptide's 30-minute half-life allows it to amplify individual GH pulses by 200–300% without disrupting the natural pulsatile secretion pattern that prevents receptor downregulation.
Somatostatin tone at the time of injection significantly modulates GH response. Administration during fasting or low-somatostatin windows (upon waking, pre-sleep) maximises pulse amplitude.
Unlike DAC-conjugated variants with 6–8 day half-lives, no DAC clears before the next endogenous pulse, preserving the hypothalamic-pituitary feedback loop and receptor sensitivity across extended protocols.
Proper reconstitution with bacteriostatic water and refrigerated storage at 2–8°C are non-negotiable. Temperature excursions or improper mixing cause irreversible peptide aggregation that renders the compound inactive.

CJC-1295 No DAC Mechanism of Action — Growth Hormone Pulse Dynamics

Research published in the Journal of Clinical Endocrinology & Metabolism found that synthetic GHRH analogues with shortened half-lives preserve physiological growth hormone (GH) pulse amplitude while avoiding the receptor desensitisation seen with continuous GHRH exposure. CJC-1295 no DAC (also called Modified GRF 1-29) operates through this exact mechanism. Transient receptor occupancy that mirrors the body's natural secretion pattern rather than replacing it. The compound binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering endogenous GH release within 15–30 minutes of administration, then clears from circulation before the next physiological pulse occurs.

Our team has guided researchers through peptide protocol design for over a decade. The difference between preserving natural pulsatility and inadvertently suppressing it comes down to understanding receptor kinetics. Something most protocol guides never explain.

What is the mechanism of action for CJC-1295 no DAC?

CJC-1295 no DAC functions as a short-acting growth hormone-releasing hormone (GHRH) analogue with a plasma half-life of approximately 30 minutes. It binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cAMP, which triggers calcium influx and exocytosis of pre-stored GH granules. The transient receptor occupancy. Lasting 90–120 minutes post-injection. Amplifies the amplitude of endogenous GH pulses without disrupting their natural frequency, preserving the pulsatile secretion pattern essential for metabolic signalling and avoiding receptor downregulation.

Most explanations stop at 'it increases growth hormone'. But that tells you nothing about why the no DAC version exists or why pulse timing matters. The compound doesn't create new GH secretion events; it magnifies existing ones. The GHRH receptor system evolved to respond to intermittent signalling. Continuous receptor occupancy (the hallmark of DAC-conjugated variants) leads to receptor internalisation and blunted GH response within 72–96 hours. CJC-1295 no DAC avoids this by clearing before the pituitary's next scheduled pulse, allowing receptors to reset between administrations. This article covers the precise receptor binding mechanism, how pulse amplitude amplification differs from baseline elevation, the role of endogenous somatostatin in gating GH release, and why subcutaneous injection timing relative to natural GH pulses significantly affects efficacy.

GHRH Receptor Binding and Signal Transduction Cascade

CJC-1295 no DAC is a 29-amino-acid synthetic analogue of the first 29 residues of native GHRH (which contains 44 residues). The modification includes four amino acid substitutions at positions 2, 8, 15, and 27 that enhance resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). The enzyme responsible for cleaving native GHRH within 7 minutes of secretion. These substitutions extend the functional half-life from under 10 minutes to approximately 30 minutes, providing a sufficient window for receptor engagement without crossing into sustained occupancy.

When administered subcutaneously, CJC-1295 no DAC reaches peak plasma concentration within 15–30 minutes. The molecule binds to GHRH receptors. G-protein-coupled receptors (GPCRs) located on somatotroph cell membranes in the anterior pituitary. Receptor activation triggers the Gs signalling pathway: the receptor-ligand complex activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates voltage-gated calcium channels on the somatotroph cell membrane. Calcium influx into the cytoplasm triggers the fusion of GH-containing secretory vesicles with the plasma membrane, releasing pre-stored growth hormone into systemic circulation.

Here's what matters: the amplitude of this GH pulse is dose-dependent and directly proportional to receptor occupancy. A single 100mcg dose of CJC-1295 no DAC administered during a natural GH pulse window can amplify that pulse by 200–300% compared to baseline, according to pharmacokinetic data from early-phase trials. The effect peaks at 30–45 minutes post-injection and returns to baseline within 2–3 hours as the peptide is cleared through renal filtration and enzymatic degradation.

Our experience with peptide stability protocols shows that reconstitution errors. Particularly using non-bacteriostatic water or storing vials above 8°C. Cause aggregation of the peptide structure within 48–72 hours, rendering the compound inactive despite no visible change in solution clarity. Proper handling is non-negotiable.

Pulsatile Secretion Pattern Preservation vs Continuous Elevation

The distinction between CJC-1295 no DAC and its DAC-conjugated counterpart (CJC-1295 with DAC) is not trivial marketing. It represents two fundamentally different pharmacological strategies. DAC (Drug Affinity Complex) conjugation extends the peptide's half-life from 30 minutes to 6–8 days by binding the molecule to serum albumin, creating a sustained-release depot effect. This produces continuous, low-level GHRH receptor occupancy that elevates baseline GH and IGF-1 levels but flattens the natural pulsatile pattern.

Physiological GH secretion occurs in discrete pulses. Typically 6–12 pulses per 24-hour period, with the largest pulses occurring during slow-wave sleep. These pulses are not random: they are gated by the opposing actions of GHRH (stimulatory) and somatostatin (inhibitory), both released from the hypothalamus in a coordinated rhythm. Somatostatin acts as a functional 'off switch' between pulses, allowing GHRH receptors to recycle and resensitise. When GHRH receptor occupancy is continuous. As with DAC variants. Somatostatin cannot fully suppress GH release between pulses, and the pituitary compensates by downregulating receptor expression.

Studies on chronic GHRH infusion in animal models demonstrate receptor internalisation and reduced GH response to subsequent GHRH challenge within 72 hours of continuous exposure. CJC-1295 no DAC avoids this by clearing between pulses. The peptide is administered 1–3 times daily, timed to coincide with natural GH pulse windows (upon waking, pre-workout, or before sleep). Each injection amplifies one pulse, then clears before the next, preserving the receptor's responsiveness across weeks or months of use.

The metabolic signalling downstream of pulsatile vs sustained GH elevation is not equivalent. Pulsatile GH secretion drives hepatic IGF-1 synthesis more efficiently than continuous low-level GH, and lipolytic signalling in adipose tissue is gated by the amplitude of individual GH pulses. Not cumulative GH AUC (area under the curve). This is why no DAC variants are preferred in research protocols focused on body composition rather than generalised anabolism.

Somatostatin Interaction and the Hypothalamic-Pituitary Feedback Loop

CJC-1295 no DAC does not operate in isolation. Its efficacy is modulated by endogenous somatostatin tone. Somatostatin (also called growth hormone-inhibiting hormone, or GHIH) is a 14-amino-acid peptide released from the periventricular nucleus of the hypothalamus. It binds to somatostatin receptors (SSTR2 and SSTR5 subtypes) on pituitary somatotrophs, inhibiting adenylyl cyclase and reducing intracellular cAMP. The exact opposite of GHRH's action.

Somatostatin secretion follows an inverse rhythm to GHRH: it peaks between GH pulses and drops during pulse windows. This creates temporal 'gates' during which GHRH signalling is most effective. Administering CJC-1295 no DAC during a period of high somatostatin tone. Such as mid-afternoon or within 90 minutes of a large carbohydrate-rich meal. Significantly blunts the GH response. Postprandial hyperglycaemia triggers somatostatin release as part of the insulin-GH axis, which is why researchers often administer GHRH analogues in a fasted state or at least 2 hours post-meal.

One mechanism rarely discussed: CJC-1295 no DAC's short half-life means it cannot override somatostatin inhibition the way long-acting GHRH analogues attempt to. If somatostatin tone is elevated at the time of injection, the GH pulse will be attenuated regardless of peptide dose. This is not a flaw. It's a feature that preserves the hypothalamic-pituitary feedback loop. The pituitary remains responsive to endogenous regulatory signals rather than being hijacked by sustained exogenous GHRH.

Negative feedback also operates at the level of IGF-1, which is synthesised primarily in the liver in response to GH. Elevated IGF-1 suppresses GHRH release from the hypothalamus and directly inhibits pituitary GH secretion. CJC-1295 no DAC protocols that produce supraphysiological IGF-1 elevation (typically through concurrent use of other secretagogues) will eventually suppress endogenous GH pulses. The peptide amplifies what remains, but the baseline pulse frequency declines. This is why peptide cycling and periodic IGF-1 monitoring are standard in research settings.

CJC-1295 No DAC Mechanism of Action Detailed: Comparison

Parameter	CJC-1295 No DAC	CJC-1295 With DAC	Native GHRH (1-44)	Professional Assessment
Plasma Half-Life	~30 minutes	6–8 days	<7 minutes	No DAC preserves pulsatile physiology; DAC trades pulse fidelity for convenience
Receptor Occupancy Pattern	Transient (90–120 min)	Continuous (168+ hours)	Transient (<15 min)	Transient occupancy prevents receptor downregulation across multi-week protocols
GH Pulse Amplification	200–300% above baseline	50–80% sustained elevation	100–150% (reference)	No DAC produces higher peak amplitude; DAC raises baseline without pulse distinction
Dosing Frequency	1–3x daily	Once weekly	Continuous endogenous	No DAC requires protocol adherence; DAC simplifies but risks tolerance
Somatostatin Sensitivity	Fully responsive	Partially overridden	Fully responsive	No DAC respects hypothalamic gating; DAC disrupts feedback loop
Receptor Desensitisation Risk	Minimal (clears between pulses)	High (continuous occupancy)	None (physiological rhythm)	Receptor recycling time between doses is critical for sustained efficacy

What If: CJC-1295 No DAC Scenarios

What If I Inject CJC-1295 No DAC Immediately After a High-Carb Meal?

The GH pulse will be significantly attenuated or absent. Postprandial hyperglycaemia stimulates somatostatin release, which directly inhibits GHRH receptor signalling at the pituitary level. Insulin and somatostatin co-release creates a refractory period lasting 90–120 minutes during which GHRH analogues produce minimal GH response regardless of dose. Administer the peptide at least 2 hours post-meal or during fasting windows to avoid this interaction.

What If I Miss a Scheduled Dose in a Multi-Dose Daily Protocol?

Skip the missed dose and resume at the next scheduled time. Do not double-dose. CJC-1295 no DAC's mechanism relies on amplifying endogenous pulses, not replacing them. Missing one injection means one un-amplified pulse, which has negligible impact over a multi-week protocol. Doubling the dose at the next administration risks supraphysiological GH elevation that could trigger acute insulin resistance or hypoglycaemia.

What If the Reconstituted Peptide Was Left at Room Temperature Overnight?

The peptide is likely denatured and inactive. Lyophilised CJC-1295 no DAC is stable at room temperature, but once reconstituted, the peptide structure is vulnerable to thermal degradation above 8°C. Aggregation begins within 12–24 hours at 20–25°C, breaking the critical disulfide bonds and amino acid alignment required for receptor binding. No home test can verify potency. Discard the vial and reconstitute a fresh dose.

The Overlooked Truth About CJC-1295 No DAC Mechanism of Action Detailed

Here's the honest answer: CJC-1295 no DAC is not a standalone growth hormone booster. It's a pulse amplifier. If your endogenous GH secretion is already suppressed (due to chronic sleep deprivation, insulin resistance, or hypothalamic dysfunction), the peptide has very little baseline signal to amplify. Researchers who expect dramatic IGF-1 elevation from no DAC alone are often disappointed because the mechanism requires functional pituitary somatotrophs and intact hypothalamic rhythms. The peptide is most effective in individuals with preserved GH pulse architecture who want to increase pulse amplitude without disrupting frequency. It's a precision tool, not a sledgehammer.

CJC-1295 no DAC mechanism of action detailed reveals why pulse timing matters more than total daily dose. A 100mcg injection administered at the wrong time. Mid-afternoon during high somatostatin tone, or within 90 minutes of a meal. Produces less GH output than a 50mcg dose timed to coincide with an endogenous pulse window. The peptide doesn't override your biology; it works with it. Protocols that ignore circadian GH rhythms are fundamentally misunderstanding what no DAC does at the receptor level. Amplification only works when there's something to amplify. And that something is gated by somatostatin, insulin, sleep quality, and hypothalamic GHRH release patterns you cannot directly control.

The transient receptor occupancy that defines CJC-1295 no DAC mechanism of action detailed is both its strength and its limitation. You get physiological fidelity and minimal receptor desensitisation, but you sacrifice the convenience of once-weekly dosing. Researchers committed to preserving long-term GH responsiveness consistently choose no DAC over DAC variants, even when it means multiple daily injections. The alternative. Flattened pulses and progressive receptor tolerance. Undermines the entire point of GHRH agonist use. When we work with research teams designing extended peptide protocols, this is the single most important mechanistic distinction we emphasise: pulse fidelity is not negotiable if the goal is sustained efficacy beyond 8–12 weeks.

Our small-batch synthesis process at Real Peptides is designed around this principle. Every peptide, including Modified GRF 1-29, undergoes exact amino-acid sequencing verification to ensure the structural integrity required for transient receptor binding. Aggregated or misfolded peptides may pass visual inspection but fail at the receptor level, producing inconsistent or absent GH response. You can explore our full approach to research-grade peptide synthesis in our full peptide collection.

The peptide's short half-life is not a bug. It's the entire design rationale. Sustained receptor occupancy is easy to engineer (just add DAC), but it trades physiological rhythm for convenience. The researchers who understand CJC-1295 no DAC mechanism of action detailed at the receptor kinetics level are the ones who see consistent results across months of use, because they respect the biology the peptide was designed to work within. That requires timing, proper reconstitution, and an understanding that amplification is conditional. Not guaranteed. If that sounds more complex than 'inject and forget,' that's because it is. Precision peptide protocols aren't simple, but they're the only approach that preserves the endogenous systems you're trying to enhance rather than replacing them outright.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions